Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? (Q35826999)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

title

Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

Raymond Siu-Ming Wong

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

author name string

F W H Chan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

G Cheng

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

language of work or name

English

0 references

publication date

1 May 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Clinical Pharmacology

11 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

page(s)

582-587

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

11 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Evolving concepts in the treatment of venous thromboembolism: the role of factor Xa inhibitors

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Pharmacotherapy of heparin- induced thrombocytopenia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Genetic polymorphisms in assessing interindividual variability in delivered dose

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Long-term treatment with warfarin in Chinese population

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Potential interactions between alternative therapies and warfarin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Potentiation of warfarin by dong quai

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Traditional remedies and food supplements. A 5-year toxicological study (1991-1995).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Guidelines for prevention of thromboembolic events in valvular heart disease. Study Group of the Working Group on Valvular Heart Disease of the European Society of Cardiology

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Factors determining the maintenance dose of warfarin in Chinese patients.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

A method to determine the optimal intensity of oral anticoagulant therapy.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Bleeding complications in oral anticoagulant therapy. An analysis of risk factors.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Anticoagulants in older patients. A safety perspective

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Hemorrhagic Complications of Anticoagulant Therapy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Trial of different intensities of anticoagulation in patients with prosthetic heart valves.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Comparison of two levels of anticoagulant therapy in patients with substitute heart valves.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0.

27 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperat

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Low dose oral anticoagulation therapy in Chinese children with congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Optimal oral anticoagulant therapy in patients with mechanical heart valves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Interaction between warfarin and the herbal product quilinggao

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Interaction between warfarin and danshen (Salvia miltiorrhiza)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Racial background is a determinant factor in the maintenance dosage of warfarin.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Use of herbal medicines by patients receiving warfarin.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Dosage and control of oral anticoagulants: an international collaborative survey.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884850

Chinese herbs and warfarin potentiation by 'Danshen'

24 September 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02361.X

Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy

21 January 2018

1 reference

12 December 2020

Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients

1 reference

12 December 2020

Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study

1 reference

12 December 2020

Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil

1 reference

12 December 2020

The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats

1 reference

12 December 2020

The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics

1 reference

12 December 2020

A taste of Chinese medicine!

1 reference

12 December 2020

Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes

1 reference

12 December 2020

Determination of dosage requirements of warfarin in Iranian patients using HPLC technique

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

CYP2C9*3 allelic variant and bleeding complications

1 reference

12 December 2020

10.1111/J.1365-2125.2005.02361.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15842557%20AND%20SRC:MED&resulttype=core&format=json

11 January 2020

1 reference